Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Anna-Maria Hoffmann-Vold, MD, PhD

Oslo University Hospital
Oslo, Norway

Anna-Maria Hoffmann-Vold is the Head of the inflammatory and fibrotic rheumatic disease research area and the systemic sclerosis (SSc) outpatient clinic at the Oslo University Hospital. She is a convenor for the ERS/EULAR guideline development for connective tissue diseases (CTD) associated ILD (CTD-ILD) and a member of the EULAR Quality of Care Committee.
Dr Hoffmann-Vold’s main expertise and interest is on clinical and translational research related to SSc and other connective tissue diseases (CTDs) with an emphasis on interstitial lung disease, pulmonary arterial hypertension, development of management recommendations, conduction of clinical trials and the potential role of gut microbiota.

Presentation(s):

  • 0510: A Risk Estimation Tool for Clinical Practice to Improve Early ILD Detection in Sjögren Disease

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Avalyn: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, November 30, 2024); Calluna Pharma: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck/MSD: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, November 30, 2024); Pliant: Consultant (Terminated, April 30, 2025)

  • 1662: Efficacy and Safety of Nerandomilast in Patients with Autoimmune Disease-Related Progressive Pulmonary Fibrosis: Subgroup Analysis of the FIBRONEER-ILD trial

    Monday, October 27, 2025
    1:00 PM - 1:15 PM Central Time

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Avalyn: Consultant (Ongoing); Boehringer-Ingelheim: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, November 30, 2024); Calluna Pharma: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Merck/MSD: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Novartis: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, November 30, 2024); Pliant: Consultant (Terminated, April 30, 2025)